Related Experiment Videos

The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand

Shan-Zhong Yang1, Fei Xu1, Tong Zhou2

  • 1From the Departments of Pathology.

Insights

High levels of HOTAIR long non-coding RNA increase pancreatic cancer resistance to TRAIL therapy by epigenetically silencing the DR5 receptor. Targeting HOTAIR may overcome this resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Pancreatic cancer has a high mortality rate and often exhibits resistance to therapies like TNF-related apoptosis-inducing ligand (TRAIL).
  • Long non-coding RNAs, such as HOTAIR, are implicated in cancer pathogenesis and drug resistance.
  • The specific role of HOTAIR in pancreatic cancer's resistance to TRAIL therapy was previously unknown.

Purpose of the Study:

  • To determine the role of HOTAIR in pancreatic cancer's resistance to TRAIL-induced apoptosis.
  • To investigate the molecular mechanisms underlying HOTAIR's influence on TRAIL sensitivity.

Main Methods:

  • Comparison of HOTAIR expression levels in TRAIL-sensitive versus TRAIL-resistant pancreatic cancer cells.
  • Manipulation of HOTAIR expression (overexpression and knockdown) to assess its effect on TRAIL-induced apoptosis.
  • Analysis of TRAIL receptor DR5 expression and its regulation by HOTAIR and the epigenetic modifier EZH2.

Main Results:

  • TRAIL-resistant pancreatic cancer cells showed significantly higher HOTAIR expression compared to TRAIL-sensitive cells.
  • Overexpressing HOTAIR reduced TRAIL-induced apoptosis in sensitive cells, while HOTAIR knockdown sensitized resistant cells to TRAIL.
  • HOTAIR was found to inhibit DR5 expression by recruiting EZH2, leading to epigenetic silencing (H3K27 trimethylation) of the DR5 gene.

Conclusions:

  • High HOTAIR expression confers resistance to TRAIL therapy in pancreatic cancer by epigenetically downregulating the DR5 receptor.
  • Targeting HOTAIR presents a potential therapeutic strategy to enhance TRAIL efficacy and overcome treatment resistance in pancreatic cancer.